Literature DB >> 7040234

Attenuation of pressor responses to norepinephrine and pitressin and potentiation of pressor response to angiotensin II by captopril in human subjects.

Y Imai, K Abe, M Seino, T Haruyama, J Tajima, M Sato, T Goto, M Hiwatari, Y Kasai, K Yoshinaga, H Sekino.   

Abstract

The present study was conducted to investigate the influence of captopril on cardiochemodynamic responses in 38 normal volunteers (20- to 35-year-old men) to exogenously administered vasopressor substances. Norepinephrine (NE), 0.05, 0.1, and 0.2 micrograms/kg min-1; angiotensin II (AII), 5, 10, and 20 ng/kg min-1; and pitressin (2 mU/kg min-1) were infused for 10 minutes. Each infusion was reported twice, and the responses were reproducible. Captopril (50 mg by mouth) significantly attenuated the pressor responses to NE and pitressin, but the decrease in heart rate in response to NE and pitressin was almost the same before and after captopril treatment, suggesting that captopril potentiates reflex slowing of the heart. Captopril significantly potentiated the pressor response to AII. Attenuation of pressor response and potentiation of reflex slowing of the heart, in response to NE and pitressin, disappeared when a subdepressor dose of AII (1 ng/kg min-1) was infused in addition to captopril. Infusion of a subdepressor dose of bradykinin (BK), 0.1 microgram/kg min-1, had no influence on the pressor response to NE. In the subjects treated with indomethacin (225 mg/54 hrs), captopril still attenuated the pressor response to NE. These results suggest that captopril attenuates the pressor responses to NE and pitressin primarily by depletion of endogenous AII; decreased AII may desensitize the contraction of arterial smooth muscle and may potentiate the compensatory reflex mechanism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7040234     DOI: 10.1161/01.hyp.4.3.444

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Chronic treatment of the spontaneously hypertensive rat with captopril attenuates responses to noradrenaline in vivo but not in vitro.

Authors:  J Atkinson; M Sonnay; M Sautel; A K Fouda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

Review 2.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

3.  Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine.

Authors:  P J Lacolley; S T Laurent; E B Billaud; M E Safar
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

4.  The effect of chronic captopril therapy on adrenergic receptors, plasma noradrenaline and the vascular responses to infused noradrenaline.

Authors:  G B Kondowe; S Copeland; A P Passmore; W J Leahey; G D Johnston
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

6.  The effect of chronic captopril therapy on platelet angiotensin II receptor density and vascular responsiveness to angiotensin II infusion.

Authors:  G B Kondowe; J G Kelly; S Copeland; G D Johnston
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor.

Authors:  A Patat; A Surjus; A Le Go; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Effects of the converting enzyme inhibitor trandolapril on short-term variability of blood pressure in essential hypertension.

Authors:  C Dutrey-Dupagne; A Girard; A Ulmann; J L Elghozi
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

9.  The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; C Richer; D Jacolot
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

10.  [Angiotensin-converting enzyme inhibition: direct and indirect mechanisms].

Authors:  K O Stumpe
Journal:  Klin Wochenschr       Date:  1985-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.